Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
VectorY has expanded its Phase 1/2 PIONEER-ALS trial of VTx-002 from 12 to 36 participants before any efficacy data is available, citing rapid enrollment and site activation. VTx-002 is a vectorized antibody designed to produce sustained antibody expression within the central nervous system against TDP-43, the protein that aggregates abnormally in up to 97% of ALS cases. The open-label, placebo-free design means the larger cohort increases biomarker and functional observations without establishing clinical benefit.
Jupiter Neurosciences has dosed the first patient in RESET, a 30-person Phase 2a trial of JOTROL, a micellar trans-resveratrol formulation, in Parkinson's disease. The study is powered for safety, tolerability and pharmacokinetics — including cerebrospinal fluid levels — with exploratory biomarkers covering energy metabolism and inflammation, not efficacy. The same announcement disclosed that the company has engaged an adviser to evaluate a sale, licensing or other strategic transaction.
Amprion and Prema Cognition have formed a collaboration pairing a 10–15 minute digital memory assessment with seed amplification biomarker assays for neurodegenerative disease. The digital test measures memory precision rather than simple recall, aiming to flag individuals with subjective cognitive decline who score normally on conventional screening and may warrant confirmatory molecular testing. No performance data, timeline, or cost structure has been disclosed.
John Beard, who led the WHO's World Report on Ageing and Health, argues that function — not diagnosis count — is the more accurate measure of how a person is aging. Intrinsic capacity assesses five domains: cognition, mobility, psychological resilience, sensory function and vitality, and can be tracked incrementally from midlife rather than waiting decades for disease endpoints. Cohort data from England and China indicate newer generations reach a higher functional peak rather than declining more slowly, suggesting interventions can raise the ceiling, not only slow the descent.
Mission Therapeutics has begun Phase 1b dosing of MTX325, an orally bioavailable, brain-penetrant USP30 inhibitor designed to restore mitophagy — the selective clearance of damaged mitochondria — in patients with mild to moderate idiopathic Parkinson's disease. The 36-participant trial across the UK, Europe and Australia will assess safety, tolerability, biomarkers and imaging, with proof-of-mechanism data expected in late 2027. Targeting mitochondrial quality control rather than dopaminergic symptom replacement places this program among the first clinical tests of a core aging mechanism in neurodegeneration.
Renue by Science has opened a decentralized research platform allowing adults to enroll in Institutional Review Board-reviewed studies from home, contributing questionnaire responses, health data and wearable device readings across baseline, intervention and optional washout periods. Planned study topics include supplements, sleep and healthy aging, with findings intended for research summaries, scientific presentations or peer-reviewed publication. The model addresses a persistent gap in the supplement sector, where consumer products are rarely subjected to structured outcome tracking.
A post-hoc analysis of Longeveron's 49-person Phase 2a CLEAR MIND trial used free water MRI to assess neuroinflammation in Alzheimer's patients treated with laromestrocel, an allogeneic mesenchymal stem cell product. Reduced inflammatory signal in the left hippocampus and temporal-parietal cortex tracked with less atrophy, better cognitive scores, and lower plasma neurogranin. The findings are exploratory, unreviewed, and hypothesis-generating rather than confirmatory.
Prenuvo has opened an imaging biobank of more than 200,000 whole-body MRI scans to over 50 research institutions, accompanied by four initial studies. The largest reported that roughly 7% of 78,000 self-referred individuals had a clinically significant brain abnormality, including aneurysms, infarcts and meningiomas. The data come from a self-selected population, and whether detection of such findings translates into longer healthy life remains unresolved.
Tenvie Therapeutics has dosed the first participant in a Phase 1 trial of TNV313, an orally administered small molecule designed to inhibit NLRP3 and cross the blood-brain barrier. The ascending-dose study in healthy volunteers will assess safety, pharmacokinetics, central nervous system distribution and exploratory pharmacodynamic biomarkers, with preliminary data expected in the first half of 2027. NLRP3-driven inflammatory signaling is implicated in neurodegenerative, cardiometabolic and ophthalmic disease, making brain-accessible inhibition a target of interest for age-related decline.
Inmune Bio and Quantum Computing Inc. will apply quantum optimization, AI and data analytics to clinical datasets spanning preclinical work through four trials of XPro, an investigational selective inhibitor of soluble tumor necrosis factor. The objective is to identify additional diseases and biomarkers driven by the same inflammatory biology the drug targets, beginning with rare diseases that permit smaller, faster trials. Outputs from the Dirac-3S machine will be benchmarked against conventional statistical and machine learning approaches.
Diagnostic Imaging Centers of Texas is adding VoxNeuro's FDA-cleared EEG-based Cognitive Function Neuroimaging to its MRI and CT services, pairing structural scans with an objective measure of how the brain responds during attention and memory tasks. The event-related potential analysis is completed in a single visit and cleared for prescription use in adults aged 18 to 70, without providing diagnosis or clinical interpretation. No outcome data has been published on whether the test alters treatment decisions or recovery trajectories.
A Lancet Neurology study measuring 130 blood proteins across 2,385 samples from patients receiving lecanemab found that the markers tracking amyloid clearance were largely distinct from those tracking later cognitive decline. Brain-derived tau variants outperformed peripherally produced forms in distinguishing treated patients from untreated controls. The findings point toward multi-marker blood profiling as a route to understanding why identical diagnoses and identical therapies produce divergent outcomes.